|
Forecast Period
|
2025-2029
|
|
Market Size (2023)
|
USD 5.42 Billion
|
|
Market Size (2029)
|
USD 11.78 Billion
|
|
CAGR (2024-2029)
|
13.89%
|
|
Fastest Growing Segment
|
Consumables
|
|
Largest Market
|
North America
|
Market Overview
Global Short-Read Sequencing Market was valued at USD
5.42 Billion in 2023 and is anticipated to project robust growth in the
forecast period with a CAGR of 13.89% through 2029. Short read sequencing, also
known as next-generation sequencing (NGS), has revolutionized genomic research
and clinical diagnostics due to its high throughput, speed, and
cost-effectiveness. This market encompasses a wide array of technologies,
platforms, and services aimed at deciphering DNA and RNA sequences quickly and
accurately. Key players in this market include Illumina, Thermo Fisher
Scientific, Oxford Nanopore Technologies, and Pacific Biosciences, among
others, each offering innovative sequencing solutions tailored to various
research and clinical applications. The market is primarily driven by the
increasing demand for personalized medicine, advancements in genomic research,
and the rising prevalence of genetic disorders and cancers worldwide. Short
read sequencing finds extensive applications in fields such as oncology,
infectious diseases, reproductive health, agriculture, and forensics, driving
its adoption across academic research institutions, pharmaceutical companies,
clinical laboratories, and biotechnology firms.
Technological advancements such as
improved sequencing chemistries, enhanced bioinformatics tools, and the
development of portable and benchtop sequencers are further fueling market
growth, enabling broader accessibility and scalability of sequencing solutions.
However, challenges such as data analysis complexities, standardization of
protocols, and ethical considerations surrounding genomic data privacy and
consent remain significant hurdles in the widespread adoption of short read
sequencing technologies. Nonetheless, collaborations between industry players,
academic institutions, and regulatory bodies are fostering innovation and
addressing these challenges, thereby propelling the growth of the global short
read sequencing market.
Key Market Drivers
Advancements in Genomic Research
Advancements in genomic research have been
instrumental in driving the growth of the Global Short Read Sequencing Market.
The field of genomics has undergone a remarkable transformation in recent
years, fueled by technological innovations and a deeper understanding of the genetic
basis of diseases. Short read sequencing, also known as next-generation
sequencing (NGS), lies at the forefront of this revolution, offering
unprecedented capabilities for deciphering DNA and RNA sequences with high
throughput and accuracy.
One of the keyways in which advancements in genomic
research boost the short read sequencing market is by increasing the demand for
sequencing technologies. As researchers delve deeper into the complexities of
the human genome and its role in health and disease, there is a growing need
for high-throughput sequencing platforms that can efficiently analyze large
volumes of genetic data. Short read sequencing technologies fulfill this need
by providing rapid and cost-effective solutions for genome-wide analysis,
enabling researchers to explore diverse research questions and hypotheses.
Advancements in genomic research have led
to the identification of novel genetic markers, biomarkers, and therapeutic
targets, further driving the adoption of short read sequencing technologies. By
sequencing the genomes of individuals with different diseases or phenotypes,
researchers can pinpoint genetic variations associated with specific traits or
conditions. This information is invaluable for understanding disease mechanisms,
identifying potential drug targets, and developing personalized treatment
strategies. As the demand for precision medicine continues to grow, so does the
demand for short read sequencing technologies that can facilitate genomic
profiling and molecular diagnostics.
Advancements in genomic research are
driving innovation in sequencing technologies themselves. Researchers and
industry players are constantly pushing the boundaries of sequencing
technology, developing new chemistries, instrumentation, and bioinformatics
tools to enhance sequencing performance and capabilities. These innovations not
only improve the accuracy and efficiency of short read sequencing but also
reduce costs and increase accessibility, making sequencing technologies more widely
available to researchers and clinicians around the world.
Rising Prevalence of Genetic Disorders and Cancers
The rising prevalence of genetic disorders and
cancers worldwide is significantly boosting the Global Short Read Sequencing
Market. Genetic disorders, characterized by abnormalities in an individual's
DNA, encompass a wide range of conditions, including rare genetic diseases,
hereditary disorders, and chromosomal abnormalities. Similarly, cancer, a
complex genetic disease characterized by uncontrolled cell growth, is a leading
cause of morbidity and mortality globally. As the incidence of genetic
disorders and cancers continues to rise, there is an increasing demand for
accurate and comprehensive genomic analysis, driving the adoption of short read
sequencing technologies.
Short read sequencing plays a critical role in the
diagnosis, prognosis, and treatment of genetic disorders and cancers by
enabling high-throughput analysis of DNA and RNA sequences. By sequencing the
genomes or transcriptomes of patients, researchers and clinicians can identify
genetic mutations, structural variants, and gene expression patterns associated
with specific diseases or cancer subtypes. This information is invaluable for
understanding disease mechanisms, predicting disease progression, and guiding
personalized treatment strategies tailored to individual patients.
Short read sequencing technologies
facilitate the identification of actionable mutations and therapeutic targets,
paving the way for precision medicine approaches in the management of genetic
disorders and cancers. By matching patients with targeted therapies or clinical
trials based on their genomic profiles, short read sequencing technologies can
improve treatment outcomes and reduce adverse effects. Sequencing
technologies enable the monitoring of disease progression and treatment
response over time, allowing clinicians to adjust treatment regimens as needed.
The rising prevalence of genetic disorders and
cancers also underscores the importance of early detection and prevention
strategies, further driving the demand for short read sequencing technologies.
By screening individuals for genetic predispositions or risk factors associated
with certain diseases, sequencing technologies can identify at-risk populations
and facilitate early intervention or preventive measures. For example, carrier
screening using short read sequencing can identify individuals at risk of
passing on genetic disorders to their offspring, enabling informed reproductive
decisions.
Technological Advancements in Sequencing Platforms
Technological advancements in sequencing platforms
are playing a pivotal role in boosting the Global Short Read Sequencing Market.
Short read sequencing, also known as next-generation sequencing (NGS), has
undergone rapid evolution, driven by innovations in instrumentation, chemistry,
and data analysis pipelines. These advancements have not only improved the
performance and capabilities of sequencing platforms but also enhanced their
accessibility, affordability, and usability, thereby fueling market growth.
One of the key technological advancements driving
the global short read sequencing market is the development of novel sequencing
chemistries and platforms. Companies are continuously innovating to improve
sequencing accuracy, read lengths, and throughput, enabling researchers to
generate higher-quality genomic data at faster speeds and lower costs. For
example, advancements in nanopore sequencing technology have revolutionized the
field by enabling real-time, single-molecule sequencing with minimal sample
preparation requirements. Similarly, improvements in sequencing-by-synthesis
techniques have led to the development of high-throughput sequencing platforms
capable of generating billions of reads in a single run.
Advancements in instrument throughput
have significantly increased the scalability and efficiency of short read
sequencing technologies. Modern sequencing platforms can process multiple
samples simultaneously, allowing researchers to analyze large cohorts or
conduct high-throughput screening experiments with ease. This scalability is
particularly beneficial for large-scale genomic studies, population genetics
research, and clinical diagnostics, where the ability to process large volumes
of samples quickly is essential.
In addition to improvements in sequencing chemistry
and instrumentation, advancements in bioinformatics tools and data analysis
pipelines are driving market growth by facilitating the interpretation and utilization
of genomic data generated by short read sequencing platforms. As the volume and
complexity of genomic data continue to increase, there is a growing need for
sophisticated bioinformatics solutions that can handle large datasets, identify
genetic variants, and extract meaningful insights. Companies are developing
user-friendly bioinformatics platforms and software packages that enable
researchers and clinicians to analyze, annotate, and interpret genomic data
efficiently, thereby accelerating scientific discovery and clinical
decision-making.
Download Free Sample Report
Key Market Challenges
Data Analysis Complexities
One of the primary challenges hindering the Global
Short Read Sequencing Market is the complexity of data analysis. Generating
large volumes of genomic data is only the first step; analyzing and
interpreting this data present significant challenges. Short read sequencing
produces vast amounts of raw sequencing data, which must be processed, aligned,
and analyzed using sophisticated bioinformatics tools and algorithms. The
complexity of genomic data, including repetitive sequences, structural
variations, and sequencing errors, complicates data analysis and
interpretation, requiring advanced computational techniques and expertise.
Addressing this challenge requires ongoing investment in bioinformatics
research and the development of user-friendly analysis tools to streamline data
processing and enhance the accuracy and efficiency of genomic analysis.
Standardization of Protocols
Another key challenge facing the Global Short Read
Sequencing Market is the lack of standardization of protocols and workflows.
Different sequencing platforms, library preparation methods, and data analysis
pipelines may produce varying results, making it difficult to compare data
across studies or laboratories. Standardizing protocols for sample preparation,
sequencing, and data analysis is essential to ensure reproducibility,
reliability, and comparability of genomic data. Collaborative efforts between
industry stakeholders, regulatory agencies, and research communities are needed
to establish standardized protocols, guidelines, and quality control measures
for short read sequencing technologies. Initiatives such as
proficiency testing and external quality assessment programs can help validate
sequencing protocols and ensure consistent performance across different
platforms and laboratories.
Ethical Considerations and Data Privacy
Ethical considerations surrounding genomic data
privacy and consent present significant challenges for the Global Short Read
Sequencing Market. Genomic data contain sensitive information about
individuals' genetic makeup, predispositions to diseases, and familial
relationships, raising concerns about data privacy, security, and potential
misuse. Ensuring informed consent, protecting patient confidentiality, and
safeguarding genomic data from unauthorized access or disclosure are paramount.
Regulatory frameworks and guidelines governing the collection, storage, and
sharing of genomic data, such as the General Data Protection Regulation (GDPR)
in Europe and the Health Insurance Portability and Accountability Act (HIPAA)
in the United States, must be adhered to. Transparency in data
handling practices, robust data encryption methods, and secure data storage
infrastructure are essential to address ethical concerns and build trust among
patients, researchers, and stakeholders in the short read sequencing market.
Key Market Trends
Advancements in Oncology Research
Advancements in oncology research are playing a
significant role in boosting the Global Short Read Sequencing Market. Cancer, a
complex genetic disease, presents unique challenges in diagnosis, treatment,
and patient management. However, recent breakthroughs in oncology research,
coupled with advancements in short read sequencing technologies, have
revolutionized our understanding of cancer biology and treatment strategies. Short
read sequencing technologies, also known as next-generation sequencing (NGS),
have emerged as indispensable tools in oncology research. These platforms
enable comprehensive genomic profiling of tumors, providing researchers and
clinicians with valuable insights into the genetic alterations driving cancer
initiation, progression, and treatment resistance. By sequencing the genomes of
cancer cells, short read sequencing technologies can identify somatic
mutations, copy number variations, and gene expression patterns associated with
specific cancer types or subtypes.
One of the key ways in which advancements in
oncology research are boosting the Global Short Read Sequencing Market is
through the discovery of novel therapeutic targets. Genomic profiling of tumors
using short read sequencing technologies has led to the identification of
actionable mutations and molecular pathways that can be targeted with precision
therapies. For example, the discovery of oncogenic driver mutations such as
EGFR in non-small cell lung cancer (NSCLC) has paved the way for the
development of targeted therapies such as tyrosine kinase inhibitors (TKIs),
which have significantly improved outcomes for patients with EGFR-mutant NSCLC.
Advancements in oncology research have
led to the development of novel biomarkers for predicting treatment response
and prognosis. Short read sequencing technologies enable researchers to
identify predictive biomarkers such as microsatellite instability (MSI) or
tumor mutational burden (TMB), which can guide treatment decisions and help
stratify patients based on their likelihood of response to therapy. Genomic profiling of tumors using short read sequencing can
uncover mechanisms of treatment resistance, informing the development of new
therapeutic strategies to overcome resistance and improve patient outcomes.
Advancements in oncology research are
driving the adoption of short read sequencing technologies in clinical
diagnostics. Genomic profiling of tumors using short read sequencing can inform
precision oncology approaches, enabling clinicians to tailor treatment regimens
to individual patients based on their genomic profile. As precision medicine
continues to gain traction in oncology, the demand for short read sequencing
technologies in clinical diagnostics is expected to escalate, driving market
growth and innovation.
Expansion of Applications in Non-Clinical Sectors
The Global Short Read Sequencing Market is
witnessing a significant boost due to the expansion of applications in
non-clinical sectors. While short read sequencing technologies have
traditionally been associated with genomic research and clinical diagnostics,
their versatility and scalability have opened up new opportunities in
non-clinical fields such as agriculture, forensics, and environmental
monitoring. In agriculture, short read sequencing is revolutionizing crop
improvement, livestock breeding, and food safety testing. By sequencing the
genomes of plants and animals, researchers can identify genetic variations
associated with desirable traits such as yield, disease resistance, and
nutritional content. This information is invaluable for breeding programs aimed
at developing improved crop varieties and livestock breeds. Short
read sequencing technologies enable rapid and accurate detection of pathogens
and contaminants in food products, ensuring food safety and quality control.
In the field of forensics, short read sequencing is
being used for DNA profiling and identification purposes. Short read sequencing
technologies can analyze minute amounts of DNA from forensic samples such as
hair, blood, or saliva, providing valuable genetic information for criminal
investigations and identification of individuals. Short read
sequencing enables the analysis of complex DNA mixtures and degraded samples,
enhancing the accuracy and reliability of forensic analysis.
Short read sequencing technologies are
increasingly being applied in environmental monitoring and biodiversity
conservation efforts. By sequencing environmental DNA (eDNA) from soil, water,
or air samples, researchers can assess biodiversity, monitor ecosystem health,
and detect invasive species or pathogens. Short read sequencing enables
high-throughput analysis of eDNA samples, providing insights into microbial
communities, species composition, and ecological interactions. This information
is essential for conservation efforts, habitat restoration, and management of
natural resources. The expansion of applications in non-clinical sectors is
driving the demand for short read sequencing technologies and fueling market
growth. As the versatility and scalability of short read sequencing platforms
continue to improve, the adoption of these technologies in agriculture,
forensics, and environmental monitoring is expected to accelerate further.
Segmental Insights
Product Insights
Based on the Product, the Consumables segment
emerged as the dominant segment in the Global Short-Read Sequencing market in
2023.
Consumables such as reagents, kits, and cartridges are essential components
required for conducting short-read sequencing experiments. These consumables
are consumed in large quantities during sample preparation, library
construction, and sequencing reactions, making them indispensable for
researchers and laboratories performing genomic analysis. The increasing
adoption of short-read sequencing technologies across various applications,
including genomics research, clinical diagnostics, and non-clinical sectors,
has fueled the demand for consumables.
Application
Insights
In 2023, the
targeted sequencing and resequencing segment asserted its dominance within the
Global Short-Read Sequencing market. This segment's ascendancy can be
attributed to its unparalleled ability to decipher genetic variations,
mutations, and biomarkers linked to particular diseases or conditions. Targeted
sequencing represents a transformative approach in genomic analysis,
facilitating precision medicine initiatives by furnishing clinicians with
invaluable insights into patients' genomic profiles. By unraveling the
intricacies of genetic makeup, targeted sequencing empowers healthcare
professionals to craft personalized treatment regimens tailored to the unique
genetic predispositions and characteristics of individual patients.
The burgeoning
adoption of precision medicine across diverse therapeutic domains, ranging from
oncology and rare diseases to pharmacogenomics, underscores the escalating
demand for targeted sequencing and resequencing technologies. In oncology, for
instance, targeted sequencing plays a pivotal role in elucidating the genetic
underpinnings of tumors, thereby informing the selection of targeted therapies
and immunotherapies with enhanced efficacy and safety profiles. Similarly, in
the realm of rare diseases, targeted sequencing serves as a beacon of hope for
patients grappling with elusive genetic disorders, enabling accurate diagnosis,
prognostication, and therapeutic intervention. The
advent of pharmacogenomics has propelled the integration of targeted sequencing
into clinical practice, revolutionizing drug discovery, development, and
prescription. By elucidating the interplay between genetic variations and drug
response, targeted sequencing empowers clinicians to prescribe medications with
optimal efficacy and minimal adverse effects, heralding a paradigm shift
towards personalized pharmacotherapy.
Download Free Sample Report
Regional Insights
North America emerged as the dominant player in the
Global Short-Read Sequencing Market in 2023, holding the largest market share. North America boasts a robust infrastructure for
genomics research and development, with a concentration of leading academic
institutions, research centers, and biotechnology companies driving innovation
in the field of short-read sequencing. The region is home to prominent
sequencing technology providers such as Illumina, Thermo Fisher Scientific, and
Pacific Biosciences, who continue to spearhead advancements in sequencing
platforms and applications. Also favorable government initiatives and funding
support for genomics research and precision medicine initiatives have
contributed to the dominance of North America in the global short-read
sequencing market.
Recent Developments
- In March 2023, QIAGEN N.V. announced the
introduction of the QIAseq Platform Partnership program, along with its first
collaboration with medical data-analysis provider SOPHiA GENETICS. This
collaboration aims to merge QIAGEN's QIAseq reagent technology for
next-generation sequencing (NGS) with the SOPHiA DDMTM digital analytics
platform.
Key Market Players
- Illumina, Inc.
- Invitae Corporation
- Thermo
Fisher Scientific, Inc.
- Pacific
Biosciences of California, Inc.
- BGI Genomics
Co., Ltd
- QIAGEN
NV
- Agilent
Technologies, Inc.
- Azenta
US, Inc.
- PerkinElmer,
Inc.
- ProPhase
Labs, Inc.
|
By
Product
|
By
End-User
|
By
Application
|
By
Region
|
- Instruments
- Consumables
- Services
|
- Academic & Research Institutes
- Hospitals & Clinics
- Pharmaceutical & Biotechnology
Companies
- Others
|
- Whole Genome Sequencing
- Whole Exome Sequencing
- Targeted Sequencing & Resequencing
- Others
|
- North America
- Europe
- Asia Pacific
- South America
- Middle East & Africa
|
| | | |
Report Scope:
In this report, the Global Short-Read Sequencing
Market has been segmented into the
following categories, in addition to the industry trends which have also been
detailed below:
- Short-Read Sequencing
Market, By
Product:
o Instruments
o Consumables
o Services
- Short-Read Sequencing
Market, By
Application:
o Whole Genome Sequencing
o Whole Exome Sequencing
o Targeted Sequencing & Resequencing
o Others
- Short-Read Sequencing
Market, By
End-User:
o Academic & Research Institutes
o Hospitals & Clinics
o Pharmaceutical & Biotechnology Companies
o Others
- Short-Read Sequencing
Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia-Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies
present in the Global Short-Read Sequencing Market.
Available Customizations:
Global Short-Read Sequencing Market report with the given market data, Tech Sci
Research offers customizations according to a company's specific needs. The
following customization options are available for the report:
Company Information
- Detailed analysis and
profiling of additional market players (up to five).
Global Short-Read
Sequencing Market is an upcoming report
to be released soon. If you wish an early delivery of this report or want to
confirm the date of release, please contact us at [email protected]